Published on 22 May 2024 on Simply Wall St. via Yahoo Finance
It's Probably Less Likely That ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Will See A Huge Pay...
Key Insights
ACADIA Pharmaceuticals' Annual General Meeting to take place on 29th of MayTotal pay for CEO Steve Davis includes US$856.6k salaryThe overall pay is comparable to the industry averageACADIA Pharmaceuticals' three-year loss to shareholders was 27% while its EPS grew by 40% over the past three years
In the past three years, the share price of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has struggled to grow and now shareholders are sitting on a loss. However, what is unusual is that EPS growth has been positive, suggesting that the share price has diverged from fundamentals. The AGM coming up on the 29th of May could be an opportunity for shareholders to bring these concerns to the board's attention. They could also influence management through voting on resolutions such as executive remuneration. Here's our take on why we think shareholders may want to be cautious of approving a raise for the CEO at the moment.